An open-label, randomized, controlled study of treatment duration of peginterferon alpha-2a monotherapy in patients with chronic hepatitis C
Not Applicable
Completed
- Conditions
- Chronic hepatitis C with genotype 2a/2b or genotype 1b and low viral load (<100 KIU/mL)
- Registration Number
- JPRN-UMIN000001067
- Lead Sponsor
- Japanese Consortium for the Study of Liver Diseases
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 270
Inclusion Criteria
Not provided
Exclusion Criteria
The following patients were excluded. 1. Concomitant herbal medication of Sho-saiko-to 2. Autoimmune hepatitis, alcoholic liver injury, or chronic liver diseases with other underlying causes 3. Allergic to pegylated interferon alpha-2a or other interferon preparations 4. Allergic to vaccine or biological preparations 5. Liver cirrhosis, decompensated liver disease, hepatocellular carcinoma, or other malignant diseases 6. Depression or psychiatric disorders 7. Other conditions considered inappropriate by attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method